HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today publication of positive Phase 2 clinical data for ZEVALIN® (ibritumomab tiuxetan) Injection in patients with mantle-cell lymphoma (MCL). The study, led by Dr. Mitchell R. Smith from Fox Chase Cancer Center in Philadelphia, published in the Journal of Clinical Oncology (JCO), the journal of the American Society of Clinical Oncology, showed that first-line consolidation with ZEVALIN treatment regimen, following initial therapy consisting of rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) given for four courses, was well tolerated and improved overall response rate (ORR= PR + CR) from 68% after RCHOP to 82% after ZEVALIN . The complete response rate (CR/CRu) improved from 19% after RCHOP to 56% after consolidation with ZEVALIN. ZEVALIN consolidation also met the primary endpoint of 50% prolongation of time to treatment failure (TTF) over that expected for R-CHOP x6 alone. 1 While there is no apparent plateau in TTF, median overall survival (OS) has not been reached, with an estimated 5-year OS of 73%.
